Literature DB >> 29224918

The regulatory network behind MHC class I expression.

Marlieke L M Jongsma1, Greta Guarda2, Robbert M Spaapen3.   

Abstract

The MHC class I pathway, presenting endogenously derived peptides to T lymphocytes, is hijacked in many pathological conditions. This affects MHC class I levels and peptide presentation at the cell surface leading to immune escape of cancer cells or microbes. It is therefore important to identify the molecular mechanisms behind MHC class I expression, processing and antigen presentation. The identification of NLRC5 as regulator of MHC class I transcription was a huge step forward in understanding the transcriptional mechanism involved. Nevertheless, many questions concerning MHC class I transcription are yet unsolved. Here we illuminate current knowledge on MHC class I and NLRC5 transcription, we highlight some remaining questions and discuss the use of quickly developing high-content screening tools to reveal unknowns in MHC class I transcription in the near future.
Copyright © 2018 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Expression; MHC class I; NLRC5; Regulation; Screen; Transcription

Mesh:

Substances:

Year:  2017        PMID: 29224918     DOI: 10.1016/j.molimm.2017.12.005

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  43 in total

Review 1.  Biological Consequences of MHC-II Expression by Tumor Cells in Cancer.

Authors:  Margaret L Axelrod; Rebecca S Cook; Douglas B Johnson; Justin M Balko
Journal:  Clin Cancer Res       Date:  2018-11-21       Impact factor: 12.531

2.  The Obligate Intracellular Bacterium Orientia tsutsugamushi Targets NLRC5 To Modulate the Major Histocompatibility Complex Class I Pathway.

Authors:  Kyle G Rodino; Haley E Adcox; Rebecca K Martin; Vaidehi Patel; Daniel H Conrad; Jason A Carlyon
Journal:  Infect Immun       Date:  2019-02-21       Impact factor: 3.441

3.  Characterization of primary models of human trophoblast.

Authors:  Megan A Sheridan; Xiaohui Zhao; Ridma C Fernando; Lucy Gardner; Vicente Perez-Garcia; Qian Li; Steven G E Marsh; Russell Hamilton; Ashley Moffett; Margherita Y Turco
Journal:  Development       Date:  2021-11-05       Impact factor: 6.868

Review 4.  HLA class I antigen processing machinery defects in antitumor immunity and immunotherapy.

Authors:  Luke Maggs; Ananthan Sadagopan; Ali Sanjari Moghaddam; Soldano Ferrone
Journal:  Trends Cancer       Date:  2021-09-03

5.  Frequent Loss of IRF2 in Cancers Leads to Immune Evasion through Decreased MHC Class I Antigen Presentation and Increased PD-L1 Expression.

Authors:  Barry A Kriegsman; Pranitha Vangala; Benjamin J Chen; Paul Meraner; Abraham L Brass; Manuel Garber; Kenneth L Rock
Journal:  J Immunol       Date:  2019-08-30       Impact factor: 5.422

6.  The SPPL3-Defined Glycosphingolipid Repertoire Orchestrates HLA Class I-Mediated Immune Responses.

Authors:  Marlieke L M Jongsma; Antonius A de Waard; Matthijs Raaben; Tao Zhang; Birol Cabukusta; René Platzer; Vincent A Blomen; Anastasia Xagara; Tamara Verkerk; Sophie Bliss; Xiangrui Kong; Carolin Gerke; Lennert Janssen; Elmer Stickel; Stephanie Holst; Rosina Plomp; Arend Mulder; Soldano Ferrone; Frans H J Claas; Mirjam H M Heemskerk; Marieke Griffioen; Anne Halenius; Hermen Overkleeft; Johannes B Huppa; Manfred Wuhrer; Thijn R Brummelkamp; Jacques Neefjes; Robbert M Spaapen
Journal:  Immunity       Date:  2020-12-02       Impact factor: 31.745

7.  Spatial Analysis and Clinical Significance of HLA Class-I and Class-II Subunit Expression in Non-Small Cell Lung Cancer.

Authors:  Ila J Datar; Sacha C Hauc; Shruti Desai; Nicole Gianino; Brian Henick; Yuting Liu; Kostas Syrigos; David L Rimm; Paula Kavathas; Soldano Ferrone; Kurt A Schalper
Journal:  Clin Cancer Res       Date:  2021-02-18       Impact factor: 13.801

8.  Therapeutically Increasing MHC-I Expression Potentiates Immune Checkpoint Blockade.

Authors:  Shengqing Stan Gu; Wubing Zhang; Xiaoqing Wang; Peng Jiang; Nicole Traugh; Ziyi Li; Clifford Meyer; Blair Stewig; Yingtian Xie; Xia Bu; Michael P Manos; Alba Font-Tello; Evisa Gjini; Ana Lako; Klothilda Lim; Jake Conway; Alok K Tewari; Zexian Zeng; Avinash Das Sahu; Collin Tokheim; Jason L Weirather; Jingxin Fu; Yi Zhang; Benjamin Kroger; Jin Hua Liang; Paloma Cejas; Gordon J Freeman; Scott Rodig; Henry W Long; Benjamin E Gewurz; F Stephen Hodi; Myles Brown; X Shirley Liu
Journal:  Cancer Discov       Date:  2021-02-15       Impact factor: 38.272

Review 9.  Protein Arginine Methylation: An Emerging Modification in Cancer Immunity and Immunotherapy.

Authors:  Weijing Dai; Jianguo Zhang; Siqi Li; Fajian He; Qiao Liu; Jun Gong; Zetian Yang; Yan Gong; Fang Tang; Zhihao Wang; Conghua Xie
Journal:  Front Immunol       Date:  2022-04-14       Impact factor: 8.786

Review 10.  NLRC5: A Potential Target for Central Nervous System Disorders.

Authors:  Lu Zhang; Cui Jiao; Lingjuan Liu; Aiping Wang; Li Tang; Yi Ren; Peng Huang; Jie Xu; Dingan Mao; Liqun Liu
Journal:  Front Immunol       Date:  2021-06-18       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.